NRBO logo

NeuroBo Pharmaceuticals (NRBO) Company Overview

Profile

Full Name:

MetaVia Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

August 5, 2016

Indexes:

Not included

Description:

NeuroBo Pharmaceuticals is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases. They aim to improve the lives of patients with conditions like Alzheimer's and Parkinson's by creating new treatments that target the underlying causes of these disorders.

Events Calendar

Earnings

Next earnings date:

May 9, 2025

Recent quarterly earnings:

Nov 7, 2024

Recent annual earnings:

Apr 15, 2021
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Dec 21, 2023

Analyst ratings

Recent major analysts updates

Dec 30, 24 HC Wainwright & Co.
Buy
May 8, 24 Maxim Group
Buy
Dec 7, 22 Ladenburg Thalmann
Buy
Feb 1, 21 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

FAQ

  • What is the ticker symbol for NeuroBo Pharmaceuticals?
  • Does NeuroBo Pharmaceuticals pay dividends?
  • What sector is NeuroBo Pharmaceuticals in?
  • What industry is NeuroBo Pharmaceuticals in?
  • What country is NeuroBo Pharmaceuticals based in?
  • When did NeuroBo Pharmaceuticals go public?
  • Is NeuroBo Pharmaceuticals in the S&P 500?
  • Is NeuroBo Pharmaceuticals in the NASDAQ 100?
  • Is NeuroBo Pharmaceuticals in the Dow Jones?
  • When was NeuroBo Pharmaceuticals's last earnings report?
  • When does NeuroBo Pharmaceuticals report earnings?
  • Should I buy NeuroBo Pharmaceuticals stock now?

What is the ticker symbol for NeuroBo Pharmaceuticals?

The ticker symbol for NeuroBo Pharmaceuticals is NASDAQ:NRBO

Does NeuroBo Pharmaceuticals pay dividends?

No, NeuroBo Pharmaceuticals does not pay dividends

What sector is NeuroBo Pharmaceuticals in?

NeuroBo Pharmaceuticals is in the Healthcare sector

What industry is NeuroBo Pharmaceuticals in?

NeuroBo Pharmaceuticals is in the Biotechnology industry

What country is NeuroBo Pharmaceuticals based in?

NeuroBo Pharmaceuticals is headquartered in United States

When did NeuroBo Pharmaceuticals go public?

NeuroBo Pharmaceuticals's initial public offering (IPO) was on August 5, 2016

Is NeuroBo Pharmaceuticals in the S&P 500?

No, NeuroBo Pharmaceuticals is not included in the S&P 500 index

Is NeuroBo Pharmaceuticals in the NASDAQ 100?

No, NeuroBo Pharmaceuticals is not included in the NASDAQ 100 index

Is NeuroBo Pharmaceuticals in the Dow Jones?

No, NeuroBo Pharmaceuticals is not included in the Dow Jones index

When was NeuroBo Pharmaceuticals's last earnings report?

NeuroBo Pharmaceuticals's most recent earnings report was on Nov 7, 2024

When does NeuroBo Pharmaceuticals report earnings?

The next expected earnings date for NeuroBo Pharmaceuticals is May 9, 2025

Should I buy NeuroBo Pharmaceuticals stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions